Wet Age-Related Macular Degeneration
VIDEO: EYP-1901 found to be ‘extremely safe,’ efficacious in first results
NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, David S. Boyer, MD, discusses 6-month results of the DAVIO trial, investigating EYP-1901 (EyePoint Pharmaceuticals) in patients with wet AMD.
BLOG: Cross my heart and hope to die, or stick a needle in my eye?
In the cover story of this issue of Ocular Surgery News, we explore emerging treatments for the subset of patients with dry age-related macular degeneration who have geographic atrophy.
Sustained delivery of pan-VEGF inhibitor may reduce treatment burden in wet AMD
NEW ORLEANS — Patients with wet age-related macular degeneration experienced a reduced treatment burden with sustained delivery sunitinib, according to a study presented here.
VIDEO: EyePoint shares phase 1 positive data for wet AMD treatment
NEW ORLEANS —Nancy Lurker, CEO and board director at EyePoint Pharmaceuticals, discusses topline results of the phase 1 DAVIO study of EYP-1901 for the treatment of wet age-related macular degeneration at the Eyecelerator meeting.
COVID-related injection reductions in wet AMD correlated with worse visual outcomes
VIDEO: Suprachoroidal delivery ‘brings gene therapy into the office setting’ for wet AMD
In a video interview, Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, talked about suprachoroidal delivery of Regenxbio’s gene therapy RGX-314 for neovascular age-related macular degeneration.
VIDEO: Expert discusses ‘remarkable’ data from ARCHWAY trial in wet AMD
Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, discussed results from the ARCHWAY phase 3 trial of the Port Delivery System with ranibizumab presented at the ASRS annual meeting.
VIDEO: Home monitoring, emerging technologies may change way AMD is managed
NEW YORK — Andrew A. Moshfeghi, MD, MBA, discusses upcoming changes in the management of age-related macular degeneration in his presentation at OSN New York Retina.
Curacle, Théa reach rights agreement for potential first oral therapy for wet AMD and DME
CRT fluctuations during wet AMD treatment significantly affect BCVA
Fluctuations in central retinal thickness appear to significantly affect best corrected visual acuity in patients with neovascular age-related macular degeneration, according to a study in the European Journal of Ophthalmology.